In this recent Molecular Tumor Board, our Medical Affairs team reviewed a case of gastrointestinal stromal tumor (GIST) with a confirmed KIT mutation, highlighting how NGS-based Comprehensive Genomic Profiling (CGP) informs treatment. The discussion explored the biology of the kinase family and how molecular testing can differentiate alterations that may be sensitive or resistant to specific kinase inhibitors. This case underscores the power of precision medicine in guiding targeted therapy and improving outcomes in GIST.
